Posts by Mourabit Halima

In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…

At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF receptor antagonist Ianalumab with Eltrombopag in patients with primary immune thrombocytopenia (ITP). The results signal a potential paradigm shift for patients who have failed first-line corticosteroid therapy, offering a new avenue for durable disease control.

At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab ("Tech-Dara") against standard-of-care regimens (Dara-Pd or Dara-Vd) in patients with relapsed/refractory multiple myeloma (RRMM), the study delivered historic results. The Tech-Dara combination achieved a Hazard Ratio (HR) for progression-free survival of 0.17—the most profound efficacy signal reported to date for BCMA-targeted therapies—signaling a potential "functional cure" for patients with early relapse.

At the 67th American Society of Hematology (ASH) Annual Meeting in 2025, a groundbreaking Late-Breaking Abstract (LBA) presented by Professor Phoebe Joy Ho (Royal Prince Alfred Hospital, Australia) signaled a potential paradigm shift in the treatment of multiple myeloma. The preliminary results from the Phase 1 inMMyCAR study of KLN-1010—the first in vivo anti-BCMA CAR-T therapy—demonstrated that deep molecular responses can be achieved without the complex logistics of ex vivo manufacturing or the toxicities associated with lymphodepleting chemotherapy.

In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses…